OKlahoma Nitrone-007: novel treatment for diffuse intrinsic pontine glioma
- PDF / 4,375,296 Bytes
- 16 Pages / 595.276 x 790.866 pts Page_size
- 7 Downloads / 213 Views
Journal of Translational Medicine Open Access
RESEARCH
OKlahoma Nitrone‑007: novel treatment for diffuse intrinsic pontine glioma Lincy Thomas1,3,9, Nataliya Smith1, Debra Saunders1, Michelle Zalles1,4, Rafal Gulej1,7, Megan Lerner5, Kar‑Ming Fung2,6, Angel M. Carcaboso8 and Rheal A. Towner1,2,4,6*
Abstract Background: Diffuse intrinsic pontine glioma (DIPG) is the most common brainstem cancer in childhood. This rapidly progressing brainstem glioma holds a very dismal prognosis with median survival of less than 1 year. Despite extensive research, no significant therapeutic advancements have been made to improve overall survival in DIPG patients. Methods: Here, we used an orthotopic xenograft pediatric DIPG (HSJD-DIPG-007) mouse model to monitor the effects of anti-cancer agent, OKlahoma Nitrone-007 (OKN-007), as an inhibitor of tumor growth after 28 days of treat‑ ment. Using magnetic resonance imaging (MRI), we confirmed the previously described efficacy of LDN-193189, a known activin A receptor, type I (ACVR1) inhibitor, in decreasing tumor burden and found that OKN-007 was equally efficacious. Results: After 28 days of treatment, the tumor volumes were significantly decreased in OKN-007 treated mice (p
Data Loading...
